Ignite Creation Date:
2024-05-06 @ 11:01 AM
Last Modification Date:
2024-10-26 @ 12:38 PM
Study NCT ID:
NCT03409614
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-25
First Post:
2018-01-10
Brief Title:
Combinations of Cemiplimab Anti-PD-1 Antibody and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Organization Data
Organization:
Regeneron Pharmaceuticals
Class:
INDUSTRY
Study ID:
R2810-ONC-16113
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Regeneron Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |